Contribute Try STAT+ Today

After years of failed attempts to treat Alzheimer’s disease by targeting a toxic brain plaque called amlyoid, a critical mass of scientists turned their attention to a seemingly more promising target: a tangled cranial protein called tau. But the failure of a closely watched tau treatment suggests history may repeat itself for neurology’s next-best idea.

On Wednesday, the Swiss drug maker AC Immune said its anti-tau antibody missed its primary and secondary goals in a placebo-controlled study that enrolled more than 450 people with early-stage Alzheimer’s. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • It’s not “a toxic brain plaque called amlyoid”. Plaques are made of a type of amyloid called amyloid-beta plus other non-amyloid components. And it’s not clear that they’re toxic. They may be a protective reaction to an environmental threat, such as a pathogen or a chemical toxin.

  • Scientific breadcrumbs is a great description of the amyloid hypothesis’ very slow demise.

Comments are closed.